Pharmacologic therapy for intermittent claudication

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 526-553

  Dobesh, Paul P ^a,d   Stacy, Zachary A ^b,c   Persson, Emily L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c ST LUKE S HOSPITAL   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis.; Buflomedil; Cilostazol; Intermittent claudication; L arginine; Naftidrofuryl; PAD; Pentoxifylline; Peripheral artery disease; Propionyl L carnitine; Statins

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; CARNITINE; CILOSTAZOL; CLOPIDOGREL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOCOSAHEXAENOIC ACID; FIBROBLAST GROWTH FACTOR; FLUNARIZINE; FOLIC ACID; GINKGO BILOBA EXTRACT; HEARTBAR; ICOSAPENTAENOIC ACID; NAFTIDROFURYL; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIPERANOMETOZINE; PLACEBO; POLICOSANOL; PROPIONYLCARNITINE; PROSTAGLANDIN E1; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN AMERICAN; AGE; ANGIOGENESIS; ANGIOPLASTY; ANKLE BRACHIAL INDEX; BLEEDING; BRAIN HEMORRHAGE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHELATION THERAPY; CHOLESTEROL BLOOD LEVEL; DELAYED DIAGNOSIS; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC ASPECT; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; INDIGESTION; INSOMNIA; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LOOSE FECES; LOW DRUG DOSE; NAUSEA; NEUROTOXICITY; NONHUMAN; PAIN; PARESTHESIA; PHYSICAL DISEASE; POLYURIA; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; RACE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; TREADMILL EXERCISE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WALKING; WEAKNESS; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUGS, INVESTIGATIONAL; EXERCISE THERAPY; GUIDELINES AS TOPIC; HUMANS; INTERMITTENT CLAUDICATION; META-ANALYSIS AS TOPIC; NAFRONYL; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PYRROLIDINES; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 66249147909     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.526     Document Type: Review

References (200)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease). J Am Coll Cardiol 2006;47:1239-312.
2. Belch JJF, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92.
3. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-15.
4. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler Thromb Vasc Biol 1998;18:185-92.
5. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national health and nutrition examination survey, 1999-2000. Circulation 2004;110:738-43.
6. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
7. Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther 2006;13(suppl 2):II3-9.
8. Bernstein EF, Fronek A. Current status of non-invasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 1982;62:473-87.
9. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962;27:645-58.
10. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med 1977;31:42-8.
11. Leng GC, Fowkes FGR. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101-9.
12. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: the Whitehall study. Circulation 1990;82:1925-31.
13. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery study. Am J Epidemiol 1992;135:331-40.
14. Powell JT, Edwards RJ, Worrell PC, et al. Risk factors associated with the development of peripheral arterial diseasein smokers: a case-control study. Atherosclerosis 1997;129:41-8.
15. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley diabetes study. Circulation 1995;91:1472-9.
16. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6.
17. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983;6:87-91.
18. Katsilambros NL, Tsapogas PC, Arvanitis MP, et al. Risk factors for lower extremity arterial disease in non-insulindependent diabetic persons. Diabet Med 1996;13:243-6.
19. Ingolfsson IO, Sigurdsson G, Sigvaldason H, et al. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol the Reykjavik study. J Clin Epidemiol 1994;47:1237-43.
20. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 1997;96:44-9.
21. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham study. J Am Geriatr Soc 1985;33:13-18.
22. Robinson K, Arheart K, Refsum H, et al, for the European COMAC Group. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97:437-43.
23. Taylor LM Jr, DeFrang RD, Harris EJ Jr, et al. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36.
24. Molgaard J, Malinow MR, Lassvik C, et al. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992;231:273-9.
25. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-8.
26. Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication: incidence in the Framingham study. Circulation 1970;41:875-83.
27. Collins TC, Peterson NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003;163:1469-74.
28. Margolis J, Barron JJ, Grochulski D. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005;11:727-34.
29. Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005;23:733-42.
30. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
31. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
32. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
33. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75:894-903.
34. The U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
35. Yusuf S, Sleight P, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
36. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.
37. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88.
38. Heart Protection Study Collaborative Group. MRC/BNF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
40. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive versus single-stage treadmill tests for the evaluation of claudication. Med Sci Sports Exer 1991;23:402-8.
41. Chaudhary H, Holland A, Dormandy J. Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication. Vasc Med 1997;2:93-7.
42. Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology 1987;38:651-6.
43. Spitzer S, Bach R, Schieffer H. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II: a review. Int Angiol 1992;11:204-10.
44. Barletta G, Perna S, Sabba C, Catalano A, O'Boyle C, Brevetti G. Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance. Vasc Med 1996;1:3-7.
45. Breek JC, Hamming JF, De Vries J, Aquarius AD, van Berge Henegouwen DP. Quality of life in patients with intermittent claudication using the World Health Organization (WHO) questionnaire. Eur J Vasc Endovasc Surg 2001;21:118-22.
46. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990;2:142-52.
47. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-15.
48. Coyne KS, Margolis MK, Gilchrist KA, et al. Evaluating effects of methods of administration on walking impairment questionnaire. J Vasc Surg 2003;38:296-304.
49. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-53.
50. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998;28:1072-81.
51. Schiano V, Brevetti G, Sirico G, Silvestro A, Giugliano G, Chiariello M. Functional status measured by walking impairment questionnaire and cardiovascular risk prediction in peripheral arterial disease: results of the peripheral arteriopathy and cardiovascular events (PACE) study. Vasc Med 2006;11:147-54.
52. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, MA: The Health Institute, 1993.
53. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions; results from the medical outcomes study. JAMA 1989;262:907-13.
54. Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M. The medical outcomes study: an application of methods for monitoring the results of medical care. JAMA 1989;262:925-30.
55. Ware JE Jr, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston, MA: The Health Assessment Lab, New England Medical Center, 1994.
56. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 1995;33:AS264-79.
57. Izquierdo-Porrera AM, Gardner AW, Bradham DD, et al. Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication. J Vasc Surg 2005;41:625-30.
58. Ernst E. Physical exercise for peripheral vascular disease: a review. Vasa 1982;16:227-31.
59. Ernst EW, Matrai A. Intermittent claudication, exercise and blood rheology. Circulation 1987;76:1110-14.
60. Ruell PA, Imperial ES, Bonar FJ, Thursby PF, Grass GC. Intermittent claudication: the effect of physical training on walking tolerance and venous lactate concentration. Eur J Appl Physiol 1984;52:420-5.
61. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-9.
62. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Circulation 1994;90:1866-74.
63. Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg 1997;14:344-50.
64. Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease. J Vasc Surg 2008;47:303-9.
65. Larsen OA, Lassen NA. Effect of daily muscle exercise in patients with intermittent claudication. Lancet 1966;ii:1093-5.
66. Holm J, Dahllof AG, Bjorntorp P, Schersten T. Enzyme studies in muscles of patients with intermittent claudication: effect of training. Scan J Clin Lab Invest 1973;31(suppl 128):201-5.
67. Dahllof A-G, Bjorntorp P, Holm J, Schersten T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency. Eur J Clin Invest 1974;4:9-15.
68. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA 1995;274:975-80.
69. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;(2): CD000990.
70. Halperin JL, Fuster V. Meeting the challenge of peripheral arterial disease. Arch Intern Med 2003;163:877-8.
71. Treesak C, Kasemsup V, Treat-Jacobson D, Nyman JA, Hirsch AT. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 2004;9:279-85.
72. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkers FGR, on behalf of the TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(suppl S):S5A-67.
73. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline: a hemorheologic agent for the treatment of intermittent claudication. Angiology 1984;35:407-17.
74. Baker DE, Campbell RK. Pentoxifylline: a new agent for intermittent claudication. Drug Intell Clin Pharm 1985;19:345-8.
75. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994;30:603-21.
76. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
77. Schröer R. Antithrombotic potential of pentoxifylline, a hemorheologically active drug. Angiology 1985;36:387-98.
78. Ambrus JL, Ambrus CM, Taheri SA, et al. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular diseases and study of therapeutic approaches. Angiology 1984;35:418-26.
79. Angelkort B, Spürk P, Habbaba A, Mähder M. Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology 1985;36:285-92.
80. Bollinger A, Frei C. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977;1:557-62.
81. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.
82. Di Perri T, Guerrini M. Placebo-controlled double-blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 1983;34:40-5.
83. Perhoniemi V, Salmenkivi K, Sundberg S, Johnson R, Gordin H. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 1984;35:366-72.
84. Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA. Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication? Curr Med Res Opin 1984;9:35-40.
85. Strano A, Davi G, Avellone G, Novo S, Pinto A. Doubleblind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35:459-66.
86. Gallus AS, Gleadow F, Dupont P, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust NZ J Med 1985;15:402-9.
87. Roekaerts F, Deleers L. Trental in the treatment of intermittent claudication: results of long-term, placebocontrolled administration. Angiology 1984;35:396-406.
88. Lindgärde F, Jelnes R, Björkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989;80:1549-56.
89. Dettori AG, Pini M, Moratti A, et al. Acenocoumarol andpentoxifylline in intermittent claudication: a controlled clinical study. Angiology 1989;40:237-48.
90. Ernst E, Kollár L, Resch KL. Does pentoxifylline prolong walking distance in exercised claudicants? A placebocontrolled double-blind trial. Angiology 1992;43:121-5.
91. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
92. Cesarone MR, Belcaro G, Nicolaides AN, et al. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 2002;53(suppl 1):S1-5.
93. De Sanctis MT, Cesarone MR, Belcaro G, et al. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial. Angiology 2002;53(suppl 1):S13-17.
94. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996;155:1053-9.
95. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337-45.
96. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:135-46.
97. Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology 1994;45:339-45.
98. Jacoby D, Mohler ER III. Drug treatment of intermittent claudication. Drugs 2004;64:1657-70.
99. Dawson DL, Cutler BS, Meissner MH, Strandness E Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
100. Elam MB, Heckman JR, Course DB, et al. Effects of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942-7.
101. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distance in patients with intermittent claudication. J Vasc Surg 1998;27:267-75.
102. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
103. Standness DE Jr, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg 2002;36:83-91.
104. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-19.
105. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2007;(1):CD003748.
106. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: a meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939-46.
107. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999;29:269-76.
108. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-13.
109. Hiatt WR. The U.S. experience with cilostazol in treating intermittent claudication. Atheroscler Suppl 2006;6:21-31.
110. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87(suppl):D28-33.
111. Abbas R, Chow CP, Browder NJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 2000;19:178-84.
112. Packer M, Carver JR, Rodeheffer RJ, et al, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
113. Feldman AM, Bristow MR, Parmley WW, et al, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
114. Cone J, Wang S, Tandon N, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999;34:497-504.
115. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc Surg 2008;47:330-6.
116. Pastoris O, Dossena M, Gorini A, et al. Adaptation of skeletal muscle energy metabolism to repeated hypoxic-normoxic exposures and drug treatment. Arch Int Pharmacodyn Ther 1985;274:145-58.
117. Barradell LB, Brogden RN. Oral naftidrofuryl: a review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996;8:299-322.
118. Clyne CAC, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br J Surg 1980;67:347-8.
119. Trübestein G, Bohme H, Heidrich H, et al. Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study. Angiology 1984;35:701-8.
120. Adhoute G, Bacourt F, Barral M, et al. Naftidrofuryl in chronic arterial disease: results of a six-month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 1986;37(3 pt 1):160-7.
121. Adhoute G, Andreassian B, Boccalon H, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990;16(suppl 3):S75-80.
122. Moody AP, Al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(suppl 3):S44-7.
123. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta-analysis. J Cardiovasc Pharmacol 1990;16(suppl 3):S81-6.
124. Trübestein G, Balzer K, Bisler H, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984;35:500-5.
125. Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int Angiol 2001;20:337-44.
126. De Backer TLM, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev 2008;(1):CD000988.
127. Marimbert J. Lettre aux professionnels de santé pharmacovigilancec et la séurité d'emploi du bufloméil [letter to health professionals: pharmacovigilance and safety of use of buflomedil]. Saint-Denis, France: Agence françise de séurité sanitaire des produits de santé November 13, 2006.
128. Leizorovicz A, Becker F, for the Limbs International Medicinal Buflomedil (LIMB) Study Group. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebocontrolled, 4-year study. Circulation 2008;117:816-22.
129. Campbell MK, ed. Citric acid cycle. Biochemistry, 2nd ed. New York: Saunders College Publishing, 1995:365-90.
130. Brevetti G, Perna S, Sabba C, et al. Superiority of Lpropionylcarnitine versus L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Euro Heart J 1992;13:251-5.
131. Hiatt WR. Carnitine and peripheral arterial disease. Ann NY Acad Sci 2004;1033:92-8.
132. Tassani V, Cattapan F, Magnanimi L, Peschechera A. Anaplerotic effect of propionyl carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994;199:949-53.
133. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988;77:767-73.
134. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: doubleblind, placebo-controlled, dose titration, multicenter trial. J Am Coll Cardiol 1995;26:1411-16.
135. Brevetti G, Perna S, Sabba C, Martone VD, Di Iorio A, Barletta G. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-80.
136. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24.
137. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-Lcarnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22.
138. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-44.
139. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med 2000;5:11-19.
140. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-Arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007;116:188-95.
141. Boger R, Bode-Boger S, Thiele W, Junker W, Alexander K, Frolich J. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
142. Pittler MH, Ernst E. Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis 2005; 181:1-7.
143. Guinot P, Caffrey D, Lambe R, Darragh A. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis 1989;19:219-23.
144. Mahady GB. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs 2002;16:21-32.
145. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000;108:276-81.
146. Horsch S, Walther C. Ginkgo biloba special extract EGb761 in the treatment of peripheral arterial occlusive disease (PAOD): a review based on randomized, controlled studies. Int J Clin Pharmacol Ther 2004;42:63-72.
147. Ernst E, Pittler MH. Alternative therapy bias [online exclusive article]. Nature 1997;385:480. Available from http://www.nature.com/doifinder/10.1038/ 385480c0.
148. Coelho HF, Pittler MH, Ernst E. An investigation of the contents of complementary and alternative medicine journals. Altern Ther Health Med 2007;13:40-4.
149. Pepping J. Policosanol. Am J Health-Syst Pharm 2003;60:1112-14.
150. Castaño G, Más R, Fernández L, Gámez R, Illnait J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003;54:25-38.
151. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, doubleblind, placebo-controlled trial. Am Heart J 2006;152:982.e1-5.
152. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 2006;84:1543-8.
153. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006;295:2262-9.
154. Castaño G, Más R, Roca J, et al. A double-blind, placebocontrolled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999;50:123-30.
155. Castaño G, Más R, Fernández L, Gámez R, Illnait J, Fernández JC. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-25.
156. Castaño G, Más R, Gámez R, Fernández L, Illnait J. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55:361-71.
157. Fernández L, Más R, Illnait J, Fernández JC. Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res 1998;59:717-22.
158. Boyd AM, Marks J. Treatment of intermittent claudication: a reappraisal of alpha-tocopherol. Angiology 1963;14:198-208.
159. Hamilton M, Wilson GM, Armitage P, Boyd JT. The treatment of intermittent claudication with vitamin E. Lancet 1953;i:367-70.
160. Livingstone PD, Jones C. Treatment of intermittent claudication with vitamin E. Lancet 1958;ii:602-4.
161. Williams HTG, Clein LJ, Macbeth RA. Alpha-tocopherol in the treatment of intermittent claudication: a preliminary report. Can Med Assoc J 1962;87:538-41.
162. Tornwall ME, Virtamo J, Haukka JK, et al. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis 1999;147:193-7.
163. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 1998;(1):CD000987.
164. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
165. Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 suppl):S1645-54.
166. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993;88:523-33.
167. Appel LJ, Miller ER, Seidler AJ, et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993;153:1429-38.
168. Barcelli U, Glas-Greenwalt P, Pollak VE. Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 1985;39:307-12.
169. Agren JJ, Vaisanen S, Hanninen O, et al. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids 1997;57:419-21.
170. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007;(4):CD003833.
171. Woodcock BE, Smith E, Lambert WH, et al. Beneficial effect of fish oil on blood viscosity in peripheral vascular disease. Br Med J (Clin Res Ed) 1984;288:592-4.
172. Gans RO, Bilo HJ, Weersink EG, et al. Fish oil supplementation in patients with stable claudication. Am J Surg 1990;160:490-5.
173. Pedersen TR, Kjekshus J, Pyörälä K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5.
174. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64.
175. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:711-12.
176. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6.
177. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lowerextremity peripheral arterial disease. Circulation 2003;107:757-61.
178. Giri J, McDermott MM, Greenland P, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006;47:998-1004.
179. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3.
180. Bernardi D, Bartoli P, Ferreri A, Geri AB, Ieri A. Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology 1988;39:942-52.
181. Roberts DH, Tsao Y, Linge K, McLoughlin GA, Breckenridge A. Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology 1992;43:748-56.
182. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Ramipril markedly improves walking ability in patients with peripheral arterial disease. Ann Intern Med 2006;144:660-4.
183. Diehm C, Balzer K, Bisler H, et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebocontrolled double-blind trial. J Vasc Surg 1997;25:537-44.
184. Belch JJ, Bell PR, Creissen D, et al. Randomized, doubleblind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997;95:2298-302.
185. Mohler ER, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003;41:1679-86.
186. Lièvre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double blind, randomized, multicenter controlled trial. Circulation 2000;102:426-31.
187. Lièvre M, Azoulay S, Lion l, Morand S, Girre JP, Boissel JP. A dose effect study of beraprost sodium in intermittent claudication. J Cardio Pharm 1996;27:788-93.
188. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003;10:285-91.
189. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol 2007;22:458-63.
190. Vartanian SM, Sarkar R. Therapeutic angiogenesis. Vasc Endovascular Surg 2007;41:173-85.
191. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007;152:175-88.
192. Lederman RJ, Mendelsohn FO, Anderson RD, et al, for the TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8.
193. Nikol S, Baumgartner I, Van Belle E, et al, for the TALISMAN 201 Investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8.
194. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8.
195. van Royen N, Schirmer SH, Atasever B, et al. START trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage colonystimulating factor as a new treatment for peripheral vascular disease. Circulation 2005;112:1040-6.
196. Grossman PM, Mendelsohn F, Henry TD, et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153:874-80.
197. Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation 1997;96:1031-3.
198. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy in peripheral arteriosclerosis. Surg Gynecol Obstet 1991;162:122-5.
199. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication: a double-blind, placebo-controlled study. J Intern Med 1992;231:261-7.
200. van Rij AM, Solomon C, Packer SG, et al. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation 1994;90:1194-9.